top of page


IPMPC Comments on FTC's Health Breach Notification Rule Notice of Proposed Rulemaking

IPMPC, Biocom California, & CLSA Comments to California Privacy Protection Agency on Modified Proposed Regulations Implementing CPRA

IPMPC Submission to UK ICO Consultation on Anonymisation, Pseudonymisation, and Privacy Enhancing Technologies Guidance

IPMPC & Biocom California Comments to California Privacy Protection Agency on Proposed Regulations Implementing CPRA

IPMPC Submission to Brazil ANPD Consultation on International Data Transfers

IPMPC Comments on UK ICO Consultation on Draft Guidance for Research Provisions in UK GDPR and DPA 2018

EFPIA-IPMPC Comments on EDPB Recommendations

Importance of Transatlantic Data Flows to Healthcare Innovation and Delivery

EFPIA-IPMPC Submission to EDPB Regarding Controller-Processor Guidelines

Personal Data’s Role in Advancing Health Care Innovation

IPMPC Submission on EMA Discussion Paper for Medicines Developers, Data Providers, Research-Performing and Research-Supporting Infrastructures on GDPR and Secondary Use of Data for Medicines and Public Health Purposes

IPMPC White Paper: The Evolving Ethical and Legal Framework for the Use of AI in the Pharmaceutical and Medical Device Industries

Over the last century, medical science has transformed human health and dramatically increased life expectancy. The life saving treatments available today were made possible by an environment that fostered medical research. The scientific process used in medical research relies on the ability to effectively collect, analyze and reanalyze patient health information. Pharmaceutical companies collect patient health information created in controlled research settings (e.g., clinical trials to investigate an experimental drug), as well as real world patient health data.

bottom of page